Try our Advanced Search for more refined results
Amarin Pharma, Inc. et al v. United States Food & Drug Administration et al
Case Number:
1:15-cv-03588
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 18, 2016
The Amarin Win: How Cahill Gordon Took On The FDA
When Amarin Pharma this month nailed down a seismic win for Big Pharma's off-label marketing, it was the climax of a First Amendment case painstakingly developed by three seasoned attorneys at Cahill Gordon & Reindel LLP. In an interview with Law360, they discussed the case's origins, why it succeeded and where things go from here.
-
March 08, 2016
Amarin, FDA Finalize Free Speech Settlement
Amarin Pharma and the U.S. Food and Drug Administration on Tuesday finalized in New York federal court a long-awaited settlement of First Amendment litigation over restrictions on off-label promotion, capping a seminal case for oversight of prescription drug claims.
-
December 17, 2015
Amarin, FDA Off-Label Promotion Suit Stayed Until Feb.
A New York federal judge on Thursday halted a suit between Amarin Pharma Inc. and the U.S. Food and Drug Administration — in which the court had previously ruled Amarin can make certain truthful statements about off-label uses of its omega-3 drug Vascepa — while the two chisel out a settlement.
-
August 28, 2015
Amarin, FDA To Discuss Settling Off-Label Promotion Dispute
Amarin Pharma Inc. and the U.S. Food and Drug Administration have agreed to discuss settlement options following the company's landmark win in a suit in which a New York federal judge upheld drugmakers' right to truthfully promote their products' unapproved uses, Amarin's lawyers said in a Friday letter.
-
August 10, 2015
Amarin's Off-Label Victory Opens Door To More Injury Claims
Amarin Pharma Inc.'s landmark win in its New York federal suit against the U.S. Food and Drug Administration upholds drugmakers' right to truthfully promote their products' unapproved uses, but attorneys say this expanded marketing can inadvertently supply more fodder — without the FDA's imprimatur — for failure-to-warn lawsuits.
-
August 07, 2015
5 Questions After Amarin's Off-Label Marketing Triumph
A landmark court decision on Friday allowing truthful and nonmisleading off-label promotion by Amarin Pharma Inc. provides a roadmap for drugmakers to market products more freely, but attorneys say much uncertainty remains about the ruling's impact on criminal misbranding cases and False Claims Act litigation. Here are five questions raised by Amarin's victory.
-
August 07, 2015
FDA's Off-Label Marketing Rules Take Hit In Amarin Fight
A New York federal judge on Friday ruled that Amarin Pharma Inc. has a constitutional right to make certain truthful and nonmisleading statements about off-label uses of omega-3 drug Vascepa, striking a blow to the U.S. Food and Drug Administration's restrictions on product marketing.
-
July 07, 2015
Judge Grills Amarin, FDA Over Off-Label Promo Statements
A New York federal judge on Tuesday appeared unlikely to immunize Amarin Pharma Inc. from punishment by the U.S. Food and Drug Administration for engaging in off-label promotion, while nonetheless suggesting that certain truthful statements may be constitutionally protected.
-
July 06, 2015
Life Sciences Cases To Watch In The 2nd Half Of 2015
The pharmaceutical industry is poised for important court developments involving off-label marketing, biosimilars exclusivity, False Claims Act liability and the 340B drug-discount program. Here are four cases that attorneys will be tracking closely in the second half of 2015.
-
June 30, 2015
Amarin Not Backing Down In Free Speech Suit Against FDA
Amarin Pharma Inc. on Tuesday urged a New York federal judge to protect its off-label marketing of fish oil drug Vascepa, saying the U.S. Food and Drug Administration hasn't removed the threat of punishment that would violate First Amendment rights.